Pharma Tech

Alteogen signs $365m Hybrozyme licensing deal with pharma company

Aug 6, 2026, 9:36 AM

Read Full Article → Alteogen signs $365m Hybrozyme licensing deal with pharma company

Translate article text

Choose a language and wait for the translated text.

Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.